Imunon regains Nasdaq minimum bid price compliance; trading continues uninterrupted

Imunon, Inc.

Received Nasdaq Hearings Panel confirmation of regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
Common stock (IMNN) to continue trading on Nasdaq Capital Market without interruption.
CEO notes recent 15% stock dividend and momentum from Phase 2 OVATION 2 trial for IMNN-001 in ovarian cancer.
Phase 3 OVATION 3 trial for IMNN-001 successfully initiated in North America.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.